Effects of rebamipide for chronic atrophic gastritis: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
19 Jun 2020
19 Jun 2020
Historique:
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
3
7
2020
Statut:
ppublish
Résumé
Chronic atrophic gastritis (CAG) is defined as an important precancerous disease with high risk of gastric cancer. Rebamipide is a mucosal protective agent widely used in the treatment of chronic gastritis. The aim of this systematic review is to assess the efficacy and safety of rebamipide for the treatment of patients with CAG. We will perform a comprehensive retrieval in the following electronic databases: PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database (VIP), Chinese Biomedical Literature Service System (SinoMed) and other sources. Two trained researchers will select the qualified studies for data extraction and assess the quality and risk of bias, independently. Then the meta-analyses will be conducted by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Funnel plot analysis and Egger test will be used to assess the publication bias. Finally, the quality of evidence will be assessed by the GRADE system. The results of our research will be published in a peer-reviewed journal. The conclusion of our systematic review will provide evidence to judge whether rebamipide is an effective intervention for patient with CAG. 10.17605/OSF.IO/BKC3E.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic atrophic gastritis (CAG) is defined as an important precancerous disease with high risk of gastric cancer. Rebamipide is a mucosal protective agent widely used in the treatment of chronic gastritis. The aim of this systematic review is to assess the efficacy and safety of rebamipide for the treatment of patients with CAG.
METHODS AND ANALYSIS
METHODS
We will perform a comprehensive retrieval in the following electronic databases: PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database (VIP), Chinese Biomedical Literature Service System (SinoMed) and other sources. Two trained researchers will select the qualified studies for data extraction and assess the quality and risk of bias, independently. Then the meta-analyses will be conducted by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Funnel plot analysis and Egger test will be used to assess the publication bias. Finally, the quality of evidence will be assessed by the GRADE system.
RESULTS
RESULTS
The results of our research will be published in a peer-reviewed journal.
CONCLUSION
CONCLUSIONS
The conclusion of our systematic review will provide evidence to judge whether rebamipide is an effective intervention for patient with CAG.
OSF REGISTRATION NUMBER
UNASSIGNED
10.17605/OSF.IO/BKC3E.
Identifiants
pubmed: 32569191
doi: 10.1097/MD.0000000000020620
pii: 00005792-202006190-00039
pmc: PMC7310858
doi:
Substances chimiques
Anti-Ulcer Agents
0
Quinolones
0
rebamipide
LR583V32ZR
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20620Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Cancer Commun (Lond). 2019 May 2;39(1):24
pubmed: 31046840
Trials. 2014 Jul 07;15:272
pubmed: 25002101
Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261-70
pubmed: 20528113
J Clin Epidemiol. 2008 Oct;61(10):991-6
pubmed: 18538991
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):383-384
pubmed: 28465548
J Pharm Pharm Sci. 2013;16(5):821-47
pubmed: 24393558
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
BMC Gastroenterol. 2014 Feb 07;14:21
pubmed: 24502423
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
BMJ. 2019 Sep 11;366:l5016
pubmed: 31511230
Endoscopy. 2012 Jan;44(1):74-94
pubmed: 22198778
Free Radic Biol Med. 1995 Jan;18(1):117-23
pubmed: 7896165
Clin Drug Investig. 2015 Oct;35(10):665-73
pubmed: 26369655
Expert Opin Pharmacother. 2012 Dec;13(18):2625-36
pubmed: 23167300
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
Eur J Pharmacol. 1992 Feb 25;212(1):9-13
pubmed: 1313372
N Engl J Med. 2018 Mar 22;378(12):1154-1156
pubmed: 29562150
Int J Cancer. 2004 Mar;109(1):138-43
pubmed: 14735480
J Clin Med. 2019 Sep 19;8(9):
pubmed: 31546909
Evid Based Complement Alternat Med. 2017;2017:9012929
pubmed: 29138645
Cancer Res. 1992 Dec 15;52(24):6735-40
pubmed: 1458460
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
J Pharmacol Exp Ther. 2000 Nov;295(2):447-52
pubmed: 11046075
Dig Dis Sci. 2018 May;63(5):1250-1260
pubmed: 29192375
Dig Dis Sci. 2008 Nov;53(11):2896-903
pubmed: 18452057